focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJUS.L Regulatory News (JUS)

  • There is currently no data for JUS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison reviews Jupiter US Smaller Companies (JUS)

29 Nov 2018 17:50

RNS Number : 9768I
Jupiter US Smaller Companies PLC
29 November 2018
 

 

London, UK, 29 November 2018

Edison issues review on Jupiter US Smaller Companies (JUS)

Jupiter US Smaller Companies (JUS) is managed by Robert Siddles, who aims to generate long-term capital growth, while preserving capital in periods of stock market weakness, from a diversified portfolio of mid- and small-cap US equities. Since October 2017, the manager has employed a tighter investment process, increasing JUS's portfolio concentration and enhancing the sell discipline. This has proved effective; since then, the trust has outperformed its US small-cap equity benchmark by more than 15pp. Relative performance has remained robust during recent months, which have been characterised by high levels of stock market volatility.

 

JUS is currently trading at an 11.0% discount to cum-income NAV, which is wider than the 6.6% to 10.0% range of averages over the past one, three, five and 10 years. The board actively manages the discount by repurchasing shares, aiming for a maximum 8% discount in normal market conditions. The significant improvement in the trust's performance since the investment process was tightened in October 2017 suggests there is scope for the discount to narrow. US smaller companies is a low-yielding asset class; hence, JUS does not pay a dividend.

Click here to view the full report.

 

All reports published by Edison are available to download free of charge from its website

www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, +44 (0)20 3077 5720

Sarah Godfrey, +44 (0)20 3681 2519

 

investmenttrusts@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-investment-research 

Twitter www.twitter.com/Edison_Inv_Res 

YouTube www.youtube.com/edisonitv 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAEAXFNALKPFFF
Date   Source Headline
17th Mar 202110:21 amRNSNet Asset Value(s)
16th Mar 202111:11 amRNSInitiation research from QuotedData
16th Mar 20219:33 amRNSNet Asset Value(s)
15th Mar 202110:36 amRNSNet Asset Value(s)
12th Mar 202111:42 amRNSChange of Investment Manager
12th Mar 20219:39 amRNSNet Asset Value(s)
12th Mar 20217:00 amRNSHalf Year Results to 31 December 2020
11th Mar 20219:55 amRNSNet Asset Value(s)
10th Mar 20219:59 amRNSNet Asset Value(s)
9th Mar 20215:13 pmRNSTransaction in Own Shares
9th Mar 202110:26 amRNSNet Asset Value(s)
8th Mar 20215:19 pmRNSTransaction in Own Shares
8th Mar 20219:43 amRNSNet Asset Value(s)
5th Mar 20215:25 pmRNSTransaction in Own Shares
5th Mar 202110:11 amRNSNet Asset Value(s)
4th Mar 202110:43 amRNSNet Asset Value(s)
3rd Mar 202110:04 amRNSNet Asset Value(s)
2nd Mar 20219:47 amRNSNet Asset Value(s)
1st Mar 20215:27 pmRNSTransaction in Own Shares
1st Mar 202110:36 amRNSNet Asset Value(s)
26th Feb 20216:26 pmRNSTotal Voting Rights
26th Feb 20215:41 pmRNSTransaction in Own Shares
26th Feb 202111:16 amRNSNet Asset Value(s)
25th Feb 202110:16 amRNSNet Asset Value(s)
24th Feb 20215:22 pmRNSTransaction in Own Shares
24th Feb 202110:18 amRNSNet Asset Value(s)
23rd Feb 202110:33 amRNSNet Asset Value(s)
22nd Feb 202110:55 amRNSNet Asset Value(s)
19th Feb 20219:43 amRNSNet Asset Value(s)
18th Feb 20215:30 pmRNSTransaction in Own Shares
18th Feb 20219:46 amRNSNet Asset Value(s)
17th Feb 202111:04 amRNSNet Asset Value(s)
16th Feb 202110:22 amRNSNet Asset Value(s)
15th Feb 20215:20 pmRNSPortfolio Update
15th Feb 202110:13 amRNSNet Asset Value(s)
12th Feb 20215:23 pmRNSTransaction in Own Shares
12th Feb 202111:40 amRNSNet Asset Value(s)
11th Feb 20215:06 pmRNSTransaction in Own Shares
11th Feb 202110:13 amRNSNet Asset Value(s)
10th Feb 20215:10 pmRNSTransaction in Own Shares
10th Feb 202110:05 amRNSNet Asset Value(s)
9th Feb 20219:48 amRNSNet Asset Value(s)
8th Feb 20213:02 pmRNSHolding(s) in Company
8th Feb 202111:57 amRNSNet Asset Value(s)
5th Feb 20219:36 amRNSNet Asset Value(s)
4th Feb 20215:26 pmRNSTransaction in Own Shares
4th Feb 202110:45 amRNSNet Asset Value(s)
3rd Feb 20212:47 pmRNSBlock listing Interim Review
3rd Feb 20219:44 amRNSNet Asset Value(s)
2nd Feb 20215:27 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.